Allscripts Healthcare Solutions (MDRX) Is Today's Strong On High Volume Stock
Trade-Ideas LLC identified
Allscripts Healthcare Solutions
(
) as a strong on high relative volume candidate. In addition to specific proprietary factors, Trade-Ideas identified Allscripts Healthcare Solutions as such a stock due to the following factors:
- MDRX has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $39.8 million.
- MDRX has traded 398,764 shares today.
- MDRX is trading at 7.43 times the normal volume for the stock at this time of day.
- MDRX is trading at a new high 6.03% above yesterday's close.
'Strong on High Relative Volume' stocks are worth watching because major volume moves tend to indicate underlying activity such as M&A events, material stock news, analyst upgrades, insider buying, buying from 'superinvestors,' or that hedge funds and momentum traders are piling into a stock ahead of a catalyst. Regardless of the impetus behind the price and volume action, when a stock moves with strength and volume it can indicate the start of a new trend on which early investors can capitalize. In the event of a well-timed trading opportunity, combining technical indicators with fundamental trends and a disciplined trading methodology should help you take the first steps towards investment success.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in MDRX with the Ticky from Trade-Ideas. See the FREE profile for MDRX NOW at Trade-Ideas
More details on MDRX:
Allscripts Healthcare Solutions, Inc. provides clinical, financial, electronic health records (EHR), connectivity, hosting, outsourcing, analytics, patient engagement, and population health products and services in the United States and Canada. Currently there are 10 analysts that rate Allscripts Healthcare Solutions a buy, no analysts rate it a sell, and 13 rate it a hold.
The average volume for Allscripts Healthcare Solutions has been 2.8 million shares per day over the past 30 days. Allscripts Healthcare has a market cap of $2.7 billion and is part of the technology sector and computer software & services industry. The stock has a beta of 1.43 and a short float of 8.9% with 4.53 days to cover. Shares are up 10.3% year-to-date as of the close of trading on Thursday.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Analysis:
rates Allscripts Healthcare Solutions as a
. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income and revenue growth. However, as a counter to these strengths, we find that the company's return on equity has been disappointing.
Highlights from the ratings report include:
- ALLSCRIPTS HEALTHCARE SOLTNS reported significant earnings per share improvement in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past year. We feel that this trend should continue. This trend suggests that the performance of the business is improving. During the past fiscal year, ALLSCRIPTS HEALTHCARE SOLTNS continued to lose money by earning -$0.37 versus -$0.59 in the prior year. This year, the market expects an improvement in earnings ($0.46 versus -$0.37).
- The company, on the basis of net income growth from the same quarter one year ago, has significantly outperformed against the S&P 500 and exceeded that of the Health Care Technology industry average. The net income increased by 81.8% when compared to the same quarter one year prior, rising from -$17.77 million to -$3.23 million.
- After a year of stock price fluctuations, the net result is that MDRX's price has not changed very much. Although its weak earnings growth may have played a role in this flat result, don't lose sight of the fact that the performance of the overall market, as measured by the S&P 500 Index, was essentially similar. Despite the fact that it has already risen in the past year, there is currently no conclusive evidence that warrants the purchase or sale of this stock.
- The current debt-to-equity ratio, 0.48, is low and is below the industry average, implying that there has been successful management of debt levels. Although the company had a strong debt-to-equity ratio, its quick ratio of 0.77 is somewhat weak and could be cause for future problems.
- Current return on equity exceeded its ROE from the same quarter one year prior. This is a clear sign of strength within the company. Compared to other companies in the Health Care Technology industry and the overall market, ALLSCRIPTS HEALTHCARE SOLTNS's return on equity significantly trails that of both the industry average and the S&P 500.
- You can view the full Allscripts Healthcare Solutions Ratings Report.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.